Investigational drug · Phase 2
HRS-5346
Also called: MK-7262
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lipoprotein(a), Lipoprotein Disorder, Treatment of Lipoprotein Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "HRS-5346"
First trial start
2025
Feb 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-5346", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lipoprotein(a)
- Lipoprotein Disorder
- Treatment of Lipoprotein Disorder
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-5346" as an intervention, largest first.
- A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07614984 · 750 participants (planned) · Start Jun 30, 2026 · Primary completion Oct 12, 2027
Drug: MK-7262; Enlicitide and 2 more · For: Lipoprotein(a)
Sites: Alexander City, Alabama; Mobile, Alabama; Beverly Hills, California · 77 sites in all
- A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06816264 · 120 participants · Start Feb 18, 2025 · Primary completion Sep 29, 2025
Drug: HRS-5346; Placebo · For: Treatment of Lipoprotein Disorder
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06441227 · 71 participants · Start Jun 13, 2024 · Primary completion Jan 9, 2025
Drug: HRS-5346 tablets; placebo · For: Lipoprotein Disorder Disease
Sites: Suzhou, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07767513 · 60 participants (planned) · Start Sep 15, 2026 · Primary completion Feb 2027
Drug: HRS-5346; HRS-5346 · For: Lipoprotein Disorder
Sites: Chengdu, China
- Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy ParticipantsNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07752069 · 50 participants (planned) · Start Aug 2026 · Primary completion Sep 2026
Drug: HRS-5346; HRS-5346 · For: Lipoprotein Disorder
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lipoprotein(a)
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.